Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus mFOLFOX6 Neoadjuvant Therapy in Locally Advanced Colorectal Cancer
ChiCTR-OPC-17010714Phase 4Recruiting
- Sponsor
- Tianjin People's Hospital
- Start
- Feb 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in colorectal cancer (CRC), sponsored by Tianjin People's Hospital. Primary endpoints: Pathologic complete response, Objective response rate and 1 more. Started Feb 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-OPC-17010714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010714.